Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Finished

FIH-IO Development of a first-in-class inhibitor of FIH for cancer immunotherapy

Coordinator
Asociacion Centro De Investigacion Cooperativa En Biociencias Cic Biogune, Spain
Runs
1 June 2022 to 30 November 2023
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101069333

What the project is doing

In the project's own words, from its summary on CORDIS.

We plan to carry out a valorisation project for a series of novel small molecule inhibitors of Factor Inhibiting HIF (FIH) that we have developed for the treatment of lung cancer, as a next-generation therapeutic approach in the field of immuno-oncology. The valorisation plan will include: clarification of IP rights and strategy, establishing contacts with potential investors and pharma partners, and verification of the potential of start-up creation.

Moreover, valorisation activities will include progression of hits against FIH into a lead optimisation campaign with the aim of designating a candidate drug.

Topics

Who is involved

OrganisationCityCountryRole
Asociacion Centro De Investigacion Cooperativa En Biociencias Cic BioguneDerio VizcayaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI